81 related articles for article (PubMed ID: 21566911)
1. Bcl-2 gene prevents apoptosis in murine acth-secreting adenoma cells induced by bromocriptine.
Yin D; Kondo S; Takeuchi J; Morimura T; Vaux D
Int J Oncol; 1994 Jan; 4(1):187-91. PubMed ID: 21566911
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine.
Yin D; Kondo S; Takeuchi J; Morimura T
FEBS Lett; 1994 Feb; 339(1-2):73-5. PubMed ID: 7508871
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis in rat somatotrophin-secreting pituitary adenoma cells by bromocriptine.
Yin D; Kondo S; Takeuchi J; Morimura T
Oncol Res; 1993; 5(9):383-7. PubMed ID: 8038459
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression.
Yin D; Tamaki N; Kokunai T; Yasuo K; Yonezawa K
J Clin Neurosci; 1999 Jul; 6(4):326-331. PubMed ID: 10844757
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC
J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
[TBL] [Abstract][Full Text] [Related]
6. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
Li Q; Su Z; Liu J; Cai L; Lu J; Lin S; Xiong Z; Li W; Zheng W; Wu J; Zhuge Q; Wu Z
Mol Cell Endocrinol; 2014 Jan; 382(1):377-384. PubMed ID: 24184771
[TBL] [Abstract][Full Text] [Related]
7. The Effects of Smad3 on Adrenocorticotropic Hormone-Secreting Pituitary Adenoma Development, Cell Proliferation, Apoptosis, and Hormone Secretion.
Zhou YZ; Li CZ; Gao H; Zhang YZ
World Neurosurg; 2018 Jun; 114():e329-e337. PubMed ID: 29524699
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
Caccavelli L; Feron F; Morange I; Rouer E; Benarous R; Dewailly D; Jaquet P; Kordon C; Enjalbert A
Neuroendocrinology; 1994 Sep; 60(3):314-22. PubMed ID: 7969790
[TBL] [Abstract][Full Text] [Related]
9. Additional antitumoral effects of bromocriptine and radiotherapy in patients with prolactinomas or acromegaly.
Coculescu M; Alessandrescu D; Stoica T; Simionescu N; Dimitriu V; Oprescu M; Chelmu S; Urba-Navicius V; Isbăşoiu O
Endocrinologie; 1980; 18(4):277-88. PubMed ID: 7209360
[TBL] [Abstract][Full Text] [Related]
10. Rapid regression of pituitary prolactinomas during bromocriptine treatment.
Thorner MO; Martin WH; Rogol AD; Morris JL; Perryman RL; Conway BP; Howards SS; Wolfman MG; MacLeod RM
J Clin Endocrinol Metab; 1980 Sep; 51(3):438-45. PubMed ID: 6773972
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
12. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
Peillon F; Cesselin F; Bression D; Zygelman N; Brandi AM; Nousbaum A; Mauborgne A
J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
[TBL] [Abstract][Full Text] [Related]
13. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Jones TH; Figueroa CD; Smith CM; Bhoola KD
Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory action of bromocriptine and tamoxifen on the growth of human pituitary tumors in soft agar.
Arafah BM; Wilhite BL; Rainieri J; Brodkey JS; Pearson OH
J Clin Endocrinol Metab; 1983 Nov; 57(5):986-92. PubMed ID: 6619272
[TBL] [Abstract][Full Text] [Related]
16. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
[TBL] [Abstract][Full Text] [Related]
17. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas.
Lamberts SW; Verleun T; Oosterom R
Neuroendocrinology; 1982; 34(5):339-42. PubMed ID: 7078703
[TBL] [Abstract][Full Text] [Related]
18. A giant prolactinoma and the effect of chronic bromocriptine therapy on basal and TRH-stimulated serum prolactin levels.
Barrera CM; Ruiz AE; Banks WA
Horm Res; 1991; 35(3-4):167-9. PubMed ID: 1806471
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
Lu J; Chatain GP; Bugarini A; Wang X; Maric D; Walbridge S; Zhuang Z; Chittiboina P
J Clin Endocrinol Metab; 2017 Aug; 102(8):2825-2835. PubMed ID: 28505327
[TBL] [Abstract][Full Text] [Related]
20. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
